Juvenile Dermatomyositis in Patients Under 18 with Major Organ Involvement: What to Do When Initial Therapy Is Insufficient

Clinical Scenario

This protocol addresses children and adolescents under 18 years of age with juvenile dermatomyositis presenting with major organ involvement or extensive ulcerative skin disease — a severe disease course in which first-line standard treatment has not achieved the required clinical endpoints.

When the Previous Treatment Has Not Worked

The preceding treatment line for severe JDM — combining high-dose corticosteroids (methylprednisolone and prednisolone), methotrexate, and cyclophosphamide — is evaluated against a defined set of measurable targets: improvement in Childhood Myositis Assessment Scale (CMAS) score, improvement in Manual Muscle Test 8 (MMT8) score, reduction in serum creatine phosphokinase (CPK), and reduction in physician global assessment of disease activity (PGA).

Escalation to this next-line protocol is indicated when three out of four clinically inactive disease criteria — CPK ≤150 U/L, CMAS ≥48, MMT8 ≥78, PGA ≤0.2 — remain unmet.

Next-Line Approach (Partial Overview)

In this refractory setting with major organ involvement, the escalation approach involves consideration of targeted biologic therapy — either B cell depletion or a change to anti-TNF agents — used alongside additional immunosuppressive agents. The full protocol specifies the complete combination strategy and sequencing. Clinicians should be aware that certain biologic therapies used in this setting may require an extended period — up to several months — before clinical effect is observed.

Success targets: Three out of four clinically inactive disease criteria must be met: CPK ≤150 U/L, CMAS ≥48, MMT8 ≥78, PGA ≤0.2.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2016-209247

For patients with severe disease (such as major organ involvement/extensive ulcerative skin disease), addition of intravenous cyclophosphamide should be considered.
B cell depletion therapy (rituximab) can be considered as an adjunctive therapy for those with refractory disease.
Clinicians should be aware that rituximab can take up to 26 weeks to work.
Anti-TNF therapies can be considered in refractory disease; infliximab or adalimumab are favoured over etanercept.
In 2012, PRINTO published criteria defining clinically inactive disease; necessitating fulfilment of three out of four variables from CPK ≤150 U/L, CMAS ≥48, MMT8 ≥78 and PGA score of overall disease activity ≤0.2.

View source ↗